Pharmaceuticals

Qianhong Bio-pharma

Qianhong Bio-pharma released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 358.08 M, actual EPS CNY 0.0678

Qianhong Bio-pharma released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 356.26 M, actual EPS CNY 0.0126

Qianhong Bio-pharma released FY2025 earnings on April 23 After-Market (BJT), actual revenue CNY 1.571 B (forecast CNY 1.749 B), actual EPS CNY 0.32 (forecast CNY 0.36)

Qianhong Bio-pharma to Release FY2026 Q1 Earnings on April 24 After-Market BJT

Qianhong Bio-pharma to Release FY2025 Annual Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 1.749 B, EPS CNY 0.36

Qianhong Bio-pharma released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 1.215 B, actual EPS CNY 0.3065

Qianhong Bio-pharma released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 353.24 M, actual EPS CNY 0.1001

Qianhong Bio-pharma to Release FY2025 Q3 Earnings on October 30 After-Market BJT

Qianhong Bio-pharma released FY2025 Semi-Annual Earnings on August 22 After-Market (BJT), with actual revenue of CNY 861.77 M and EPS of CNY 0.2065

Qianhong Bio-pharma released FY2025 Q2 earnings on August 22 After-Market BJT, actual revenue CNY 410.89 M, actual EPS CNY 0.0776

Qianhong Bio-pharma FY2025 Semi-Annual Earnings Release on August 23, 2025 (BJT)

Shareholders of Qianhong Pharmaceutical Plan to Reduce Shares

QHRD106 Entering Phase III Clinical Trials

QinHong Pharmaceutical Progressing QHRD107 Phase II Clinical Trial and Collaborating with Bayer to Promote Compound Digestive Enzyme

Qianhong Pharmaceutical Shares Abnormal Fluctuation and Share 增持

Eastwu Securities Gives Buy Rating to Qianhong Pharmaceutical

Qianhong Pharmaceutical Introduces Progress in Biomedical Innovation Drug R&D

Qianhong Pharmaceutical Hits Limit Up for 2 Consecutive Days

Qianhong Pharmaceutical Shares Rise, Eastwu Securities Maintains Buy Rating

Eastwu Securities Report Gives Qianhong Pharmaceutical a Buy Rating

002550

Qianhong Bio-pharma announced that its revenue for the third quarter was 353 million yuan, a year-on-year increase of 0.35%; net profit was 125 million yuan, a year-on-year decrease of 1.28%. Revenue for the first three quarters was 1.215 billion yuan, a year-on-year increase of 0.61%; net profit was 383 million yuan, a year-on-year increase of 23.79%

Zhitong

Qianhong Bio-pharma: The net profit for the third quarter was 125 million yuan, a year-on-year decrease of 1.28%

Qianhong Bio-pharma announced that shareholder Wang Ke increased his holdings in the company by 9.6 million shares through block trading on June 11, 2025, raising his ownership ratio from 24.91% to 25.66%. Due to the failure to timely disclose the situation when the ownership ratio reached 25%, the Jiangsu Securities Regulatory Bureau issued a warning letter to Wang Ke on September 11, 2025, and required him to submit a written report within 10 working days

Qianhong Bio-pharma: Warned for failing to disclose and halt trading in a timely manner when the shareholding ratio reached the 25% threshold

According to the Zhitong Finance APP, Qianhong Bio-pharma released its semi-annual report for 2025, showing an operating income of 862 million yuan, a year-on-year increase of 0.72%. The net profit attributable to shareholders of the listed company was 258 million yuan, a year-on-year increase of 41.17%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 199 million yuan, a year-on-year increase of 10.71%. The basic earnings per share were 0.2065 yuan

Qianhong Bio-pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 258 million yuan, an increase of 41.17%

According to the Zhitong Finance APP, Qianhong Bio-pharma announced that the company's shareholder Mr. Zhao Gang and his concerted parties, including Jianxin Fund - Zhao Renyi - Jianxin Xinxiang No. 1 Single Asset Management Plan, plan to reduce their holdings in the company by no more than 20.9 million shares (accounting for 1.63% of the company's current total share capital and 1.67% of the total share capital excluding the shares held in the repurchase special account) through centralized bidding and block trading within three months after the announcement date, starting from 15 trading days after the disclosure of this announcement

Qianhong Bio-pharma shareholder Zhao Gang and his concerted actors plan to reduce their holdings by no more than 20.9 million shares

002940

688319

603590

In the afternoon, the innovative drug concept fluctuated and rebounded, with the high-profile stock ALK hitting the daily limit and reaching a new historical high. Previously, Han Commercial Group had two consecutive limit-ups, while Jincheng Pharmaceutical, Olymvax Biopharmaceuticals, and Jiankai Technology rose over 10%. Borui Pharmaceutical, Konruns, Qianhong Bio-pharma, and Jibeier also followed suit

Olymvax Biopharmaceuticals

Konruns

The concept of innovative drugs fluctuates and rebounds, ALK hits the limit and reaches a historical high

Qianhong Bio-pharma hit the daily limit and achieved 2 consecutive trading limits, with a cumulative increase of 20.99% over 2 days

688585

002209

002393

002923

On July 16th, at the midday close, the market showed a mixed performance, with the Shanghai Composite Index down 0.12%, the Shenzhen Component Index up 0.11%, and the ChiNext Index up 0.36%. Robotics concept stocks performed strongly, with Swancor Advanced Materials, Tech-long, and Zhejiang Rongtai among several stocks hitting the daily limit. Pharmaceutical stocks were also active, with Rundu Pharma, Lishengpharma, and Qianhong Bio-pharma hitting the daily limit. Financial stocks such as banks and insurance companies declined, with Xiamen Bank down nearly 4%. The morning trading volume was 926.4 billion, with over 3,500 stocks rising

Wallstreetcn

Swancor Advanced Materials

Tech-long

Lishengpharma

Rundu Pharma

July 16th Midday Review: The ChiNext Index rose 0.36% in half a day, and robotics concept stocks strengthened again

688799

603716

600513

300254

36Kr learned that as of the time of publication, the innovative drug concept has repeatedly strengthened, Qianhong Bio-pharma surged and hit the limit up, Thalys, JLPC, C&Y Pharmaceutical, and Haizhi Ke all reached the limit up, while HWPC rose over 10%, setting a new historical high for its stock price

36Kr

HWPC

Thalys

JLPC

C&Y Pharmaceutical

The innovative drug concept has repeatedly strengthened, and Qianhong Bio-pharma has surged to the limit

Qianhong Bio-pharma's shareholder Wang Ke has completed the shareholding increase plan, accumulating an increase of 22 million shares, accounting for 1.72% of the total share capital. The increase plan was implemented from June 24 to 25, 2025, during which Wang Ke increased his holdings by 9.6 million shares and 12.4 million shares through block trading using his own or self-raised funds

Qianhong Bio-pharma shareholder Wang Ke has completed the increase in holdings, accumulating a 1.72% stake

On June 24th, Qianhong Bio-pharma had a block trade of 9.2 million shares, with a transaction amount of 82.064 million yuan, accounting for 7.73% of the total transaction amount for the day, and the transaction price was 8.92 yuan, which was flat compared to the market closing price of 8.92 yuan

Qianhong Bio-pharma conducted a block trade today at par, with 9.2 million shares traded and a transaction amount of 82.064 million yuan

Qianhong Bio-pharma(002550.SZ)